| Therapeutic implications of cellular heterogeneity and plasticity in breast cancer MD Brooks, ML Burness, MS Wicha Cell stem cell 17 (3), 260-271, 2015 | 418 | 2015 |
| Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? ML Burness, TA Grushko, OI Olopade The Cancer Journal 16 (1), 23-32, 2010 | 243 | 2010 |
| Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone TT Price, ML Burness, A Sivan, MJ Warner, R Cheng, CH Lee, L Olivere, ... Science translational medicine 8 (340), 340ra73-340ra73, 2016 | 221 | 2016 |
| Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells YH Cheng, YC Chen, E Lin, R Brien, S Jung, YT Chen, W Lee, Z Hao, ... Nature communications 10 (1), 2163, 2019 | 199 | 2019 |
| Tunable thermal-sensitive polymer-graphene oxide composite for efficient capture and release of viable circulating tumor cells HJ Yoon, A Shanker, Y Wang, M Kozminsky, Q Jin, N Palanisamy, ... Advanced materials (Deerfield Beach, Fla.) 28 (24), 4891, 2016 | 157 | 2016 |
| RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer Y Liu, ML Burness, R Martin-Trevino, J Guy, S Bai, R Harouaka, ... Clinical Cancer Research 23 (2), 514-522, 2017 | 138 | 2017 |
| High-throughput microfluidic labyrinth for the label-free isolation of circulating tumor cells E Lin, L Rivera-Báez, S Fouladdel, HJ Yoon, S Guthrie, J Wieger, Y Deol, ... Cell systems 5 (3), 295-304. e4, 2017 | 111 | 2017 |
| Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum S Varghese, M Burness, H Xu, T Beresnev, J Pingpank, HR Alexander Annals of surgical oncology 14, 3460-3471, 2007 | 93 | 2007 |
| Interferon γ–Inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells ED Feldman, DM Weinreich, NM Carroll, ML Burness, AL Feldman, ... Annals of surgical oncology 13, 125-133, 2006 | 88 | 2006 |
| The stem cell niche in health and malignancy ML Burness, DA Sipkins Seminars in cancer biology 20 (2), 107-115, 2010 | 79 | 2010 |
| Young women with breast cancer: fertility preservation options and management of pregnancy-associated breast cancer NM Shah, DM Scott, P Kandagatla, MB Moravek, EF Cobain, ML Burness, ... Annals of surgical oncology 26, 1214-1224, 2019 | 51 | 2019 |
| Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy DL Hertz, KM Kidwell, K Vangipuram, F Li, MP Pai, M Burness, JJ Griggs, ... Clinical Cancer Research 24 (15), 3602-3610, 2018 | 49 | 2018 |
| Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure LA Marcath, KM Kidwell, AC Robinson, K Vangipuram, ML Burness, ... Pharmacogenomics 20 (02), 95-104, 2019 | 25 | 2019 |
| Characterizing circulating tumor cells isolated from metastatic breast cancer patients using graphene oxide based microfluidic assay TH Kim, HJ Yoon, S Fouladdel, Y Wang, M Kozminsky, ML Burness, ... Advanced Biosystems 3 (2), 1800278, 2019 | 23 | 2019 |
| Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy TS Jennaro, F Fang, KM Kidwell, EML Smith, K Vangipuram, ML Burness, ... Breast cancer research and treatment 180, 707-714, 2020 | 18 | 2020 |
| Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy LA Marcath, KM Kidwell, K Vangipuram, CL Gersch, JM Rae, ML Burness, ... British Journal of Clinical Pharmacology 86 (5), 880-890, 2020 | 16 | 2020 |
| Is Screening With Magnetic Resonance Imaging in BRCA Mutation Carriers a Safe and Effective Alternative to Prophylactic Mastectomy? ML Burness, OI Olopade Journal of Clinical Oncology 29 (13), 1652-1654, 2011 | 9 | 2011 |
| Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer Y Liu, R Martin-Trevino, L Shang, A Davis, M Wicha, S Liu, M Burness Cancer Research 75 (15_Supplement), 4226-4226, 2015 | 8 | 2015 |
| Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report ML Burness, EI Obeid, OI Olopade Clinical Breast Cancer 15 (2), e155-e158, 2015 | 7 | 2015 |
| First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. RC Lynch, JC Bendell, RH Advani, GS Falchook, PN Munster, MR Patel, ... Journal of Clinical Oncology 39 (15_suppl), 3006-3006, 2021 | 6 | 2021 |
